Minerva Neurosciences (NERV) Non-Current Debt (2015 - 2017)
Minerva Neurosciences (NERV) posted Non-Current Debt of $1.3 million for Q2 2017, down 48.99% on a QoQ basis from $2.6 million in Q1 2017, and down 78.69% year-over-year from $6.2 million in Q2 2016.
Minerva Neurosciences (NERV) Non-Current Debt (2015 - 2017) Analysis & Trends
Minerva Neurosciences' Non-Current Debt history runs 3 years deep, the most recent figure standing at $1.3 million for Q2 2017.
- Quarterly Non-Current Debt fell 78.69% year-over-year to $1.3 million in Q2 2017, while the trailing twelve-month figure through Jun 2017 was $1.3 million (down 78.69% YoY) and the FY2016 annual result came in at $3.8 million, down 54.83% from the prior year.
- Non-Current Debt was $1.3 million for Q2 2017 at Minerva Neurosciences, down from $2.6 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $9.6 million in Q3 2015 and bottomed at $1.3 million in Q2 2017.
- A 3-year average of $6.3 million and a median of $6.8 million in 2016 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2016 — Non-Current Debt slipped 22.74% — and 2017, when it slumped 78.69%.
- Minerva Neurosciences' Non-Current Debt stood at $8.5 million in 2015, then tumbled by 54.83% to $3.8 million in 2016, then slumped by 65.47% to $1.3 million in 2017.
- Business Quant data shows NERV's Non-Current Debt at $1.3 million in Q2 2017, $2.6 million in Q1 2017, and $3.8 million in Q4 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 1.33 Mn |
| Mar 31, 2017 | 2.60 Mn |
| Dec 31, 2016 | 3.84 Mn |
| Sep 30, 2016 | 5.05 Mn |
| Jun 30, 2016 | 6.23 Mn |
| Mar 31, 2016 | 7.38 Mn |
| Dec 31, 2015 | 8.50 Mn |
| Sep 30, 2015 | 9.61 Mn |
| Jun 30, 2015 | 8.70 Mn |
| Mar 31, 2015 | 9.55 Mn |